These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 17204717

  • 1. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL, Jones RJ, Wahl RL.
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [Abstract] [Full Text] [Related]

  • 2. Monitoring cancer treatment with PET/CT: does it make a difference?
    Weber WA, Figlin R.
    J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PET/CT for therapy response assessment in lymphoma.
    Hutchings M, Barrington SF.
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H, Fury M, Lee N, Kraus D.
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D.
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
    Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B.
    Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
    [Abstract] [Full Text] [Related]

  • 16. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL, Yeo NK, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [Abstract] [Full Text] [Related]

  • 17. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
    Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ.
    Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
    Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, Verhoef GE, Chundru S, Douglas-Nikitin V, Oliver Wong CY, Brepoels LM.
    Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
    [Abstract] [Full Text] [Related]

  • 20. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.